Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 9/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 6/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23632234 | 1.00 | MCL1 (0.39) | MCL1GHSRNR1H2NR1H3LIPE | |
| SCHEMBL30075144 | 0.91 | GPR119 (0.40) | GHSRNR1H2NR1H3LIPETACR1 | |
| SCHEMBL23631983 | 0.91 | GPR119 (0.40) | GHSRNR1H2NR1H3LIPETACR1 | |
| SCHEMBL23632352 | 0.88 | MCL1 (0.38) | MCL1GHSRNR1H2NR1H3LIPE | |
| SCHEMBL23632615 | 0.87 | GPR119 (0.39) | MCL1GHSRNR1H2NR1H3LIPE | |
| SCHEMBL23632377 | 0.87 | GPR119 (0.39) | MCL1GHSRNR1H2NR1H3LIPE | |
| SCHEMBL30065030 | 0.87 | LIPE (0.41) | MCL1LIPEGPR119 | |
| SCHEMBL23632658 | 0.86 | TACR1 (0.41) | MCL1GHSRNR1H2NR1H3LIPE | |
| SCHEMBL23632115 | 0.86 | TACR1 (0.41) | MCL1GHSRNR1H2NR1H3LIPE | |
| SCHEMBL23632326 | 0.86 | TACR1 (0.41) | MCL1GHSRNR1H2NR1H3LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-4089079-A1 | ROR GAMMA T INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-11-16 | — | — | EP | disclosed |
| WO-2021139599-A1 | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 东莞市东阳光新药研发有限公司 | 2021-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230067159-A1 | ROR-GAMMA-T INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | RORC, RORB, RORA | MCL1 860/4885GHSR 2578/4885NR1H2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.